Sanofi Sells Smallpox Vaccine to Emergent

Source: Emergent Biosolutions

Jul 18, 2017

Emergent BioSolutions has entered into an agreement to acquire Smallpox vaccine ACAM2000 from Sanofi in an all-cash transaction with a total value of up to $125 million. The deal consists of $97.5 million upfront and up to $27.5 million in contingent milestones.

ACAM2000 is the only FDA-licensed smallpox vaccine and this deal will see Emergent assume responsibility for Sanofi's existing CDC contract. The contract holds a remaining value of up to approximately $160 million for deliveries of ACAM2000 to the Strategic National Stockpile.

Read the Emergent release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments